An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors

Overall Inclusion Criteria: Provide written informed consent • Cancers as follows: Sub-study 1: Histologically or cytologically confirmed recurrent locally and/or metastatic head and neck squamous cell carcinoma with Combined Positive Score (CPS) ≥ 1 as determined by a CLIA certified and/or FDA approved test. Note: A multi-disciplinary group (including a surgeon and radiation oncologist) must agree that the patient is not a candidate for locoregional therapy. Sub-study 2: Histologically or cytologically confirmed locally advanced or metastatic cutaneous squamous cell carcinoma not amenable to definitive surgery or radiation. Sub-study 3: Histologically or cytologically confirmed locally advanced or metastatic cutaneous squamous cell carcinoma not amendable to definitive surgery or radiation. * At least one site of disease accessible to light illumination. * Measurable disease by modified RECIST 1.1. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * No prior systemic therapy administered in the recurrent and/or metastatic setting (with the exception of systemic therapy completed ≥ 6 months prior if given as part of multimodal treatment for locally advanced disease). (Sub-study 1 only). * Patients must be actively receiving single-agent, systemic anti-PD1 therapy at the time of screening (Sub-study 3 only). * Disease progression despite at least 2 months of anti-PD1 therapy at the time of screening. Progression must be confirmed by at least two …